Stock Financial Ratios, Dividends, Split History

WPZ / Access Midstream Partners, L.P financial ratios include Market Cap, Enterprise Value, Book Value, Quick Ratio, Current Ratio, NCAV, EBITDA, Profit Margin, Operating Margin, Return on Invested Capital (ROIC), Return on Assets (ROA), Return on Equity (ROE), Piotroski F-Score, Altman Z-Score, Beneish M Score and Kaplan-Zingales KZ-Index.

Valuation Metrics
Market Cap ($M)38,846.97
Enterprise Value ($M)54,589.97
Book Value ($M)23,345.00
Book Value / Share24.38
Price / Book1.66
NCAV / Sharen/a
Price / NCAVn/a
Share Statistics
Common Shares Outstanding2 18,124,096
Common Shares Outstanding 957,529,465
Scoring Models
Piotroski F-Score5.00
Altman Z ScoreN/A
Beneish M ScoreN/A
Management Effectiveness (mra)
Return on Invested Capital (ROIC)0.02
Return on Assets (ROA)0.02
Return on Equity (ROE)0.04
Balance Sheet (mrq) ($M)
Quick Ratio1.09
Current Ratio1.17
Income Statement (mra) ($M)
Revenue From Related Parties0.00
Sales Revenue Services Net5,292,000,000.00
Sales Revenue Goods Net2,718,000,000.00
Operating Income1,033.00
Net Income975.00
Cash Flow Statement (mra) ($M)
Cash From Operations2,840.00
Cash from Investing660.00
Cash from Financing660.00
Identifiers and Descriptors
Central Index Key (CIK)1483096
Related CUSIPS
96949L955 96949L905

Split History

Stock splits are used by Access Midstream Partners, L.P to keep share prices within reasonable numbers to encourage investment. If the share price of a security gets too high, a company can perform a stock split by issuing all shareholders an extra share, thereby halving the price of an individual share. If the share price gets too low, companies can do reverse splits. This is common when share prices drop below $1.00 and company's become in danger of being delisted. However, because of the cost, stock splits are not a normal business occurrence.

Coming soon

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

2018-07-17 - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

2018-07-17 - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...

Related News Stories

U.S. LNG Exports Part 2: How Do LNG Exports Benefit Midstream?

2018-07-18 seekingalpha
Last week, we discussed the step change in US LNG export capacity expected next year and the role US LNG export projects could play in filling a potential global supply gap anticipated in the coming years. In today's post, we discuss how LNG exports increase infrastructure demand to the benefit of midstream. We also discuss how LNG exports facilitate natural gas production growth, with broad benefits for midstream companies and natural gas producers. (1-0)

Trying Again: Williams Companies To Acquire Williams Partners

2018-07-07 seekingalpha
Williams Companies is attempting to acquire Williams Partners for a second time, this time as a result of the closing of a small tax loophole for MLPs, announced in March. (1-0)

Why This Time It May Be Different for Kinder Morgan Stock

2018-06-22 investorplace
There’s a lot to like about Kinder Morgan (NYSE:KMI) at the moment. The company is one of the largest pipeline owners in the U.S., at a time when the country’s crude oil production is rising. (107-1)

MLP Insights: Q2 2018

2018-06-10 seekingalpha
2018 has not stopped the wild ride for MLP investors that began in 2014. The initial euphoria of tax reform earlier in the year abated as the broad equity markets became more volatile. In mid-March as the Federal Energy Regulatory Commission (FERC) rulingdisallowing a previously accepted MLP income tax allowance saw fatigued investors exit the MLP market. While MLPs have recovered by more than 14% since the nadir in late-March,1 a new elephant has entered the room: uncertainty around the future of the MLP structure. (17-0)

Revisiting MLP Distribution Growth

2018-06-06 seekingalpha
It's a perennial favorite, with investors and industry insiders requesting it over and over again. We wanted to provide a simple number that could be referenced and compared. Something like the GDP growth rate, which on its face is a quick look at the economy, but in reality, is a simplified summary of a nuanced subject. (20-0)

CUSIP: 96949L105